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Summary
Non-Hodgkin's lymphomas (nHL) are a heterogenous group of lymphoid malignancies with a different pattern of behaviour and response
to treatment. In Europe and North America mainly B-cell lymphomas (86%) are observed. Indolent lymphomas are lymphoproliferative 
diseases with a relatively good prognosis and long natural history. They usually affect elderly people and more than 90% of cases are 
diagnosed in advanced stages of the disease. Forty percent all cases of nHL are indolent lymphomas. Indolent lymphomas are curable only
in their early stages when radiotherapy is the treatment of choice. In advanced stages chemotherapy is used. However, up till now aggressive 
chemotherapy does not improve the overall survival rate and it leads to serious adverse events. This article presents current options of mana-
gement of indolent nHL, especially using purine analogues and monoclonal antibodies.
Purine analogues (fludarabine, 2-chloro-2'desoxyadenosine- 2CdA) are thought to be very promising agents as they induce apoptosis
and have cytotoxic activity against noncycling lymphocytes which dominate in indolent lymphomas histology. In recent years monoclonal 
antibodies against antigens present on the lymphoma cells such as rituximab (Mabthera) antiCD20 or alemtuzumab (MabCampath) 
antiCD52 have been widely used.
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Postêpy w leczeniu ch³oniaków o przebiegu powolnym
Streszczenie
Ch³oniaki z³oœliwe nieziarnicze (lymphoma malignum, non Hodgkin's lymphoma) jest to heterogenna grupa nowotworów wywodz¹cych siê 
z uk³adu ch³onnego o zró¿nicowanym przebiegu klinicznym i odpowiedzi na leczenie. W Europie i Ameryce Pó³nocnej 86% przypadków 
stanowi¹ ch³oniaki B komórkowe. Ch³oniaki o przebiegu powolnym nale¿¹ do schorzeñ limfoproliferacyjnych o stosunkowo dobrym 
rokowaniu i wieloletnim przebiegu naturalnym. Zazwyczaj wystêpuj¹ u ludzi starszych i w ponad 90% przypadków rozpoznanie jest ustalane
w zaawansowanym stadium klinicznym choroby. Stanowi¹ ok. 40% wszystkich ch³oniaków. Ch³oniaki o przebiegu powolnym s¹ wyleczalne 
jedynie we wczesnych stadiach. Leczeniem z wyboru jest wówczas radioterapia. U chorych w stadiach zaawansowanych stosuje siê 
chemioterapiê. W tej grupie ch³oniaków agresywna chemioterapia nie poprawia wyników odleg³ych, a nara¿a chorych na wyst¹pienie 
powa¿nych objawów niepo¿¹danych. Artyku³ omawia wspó³czesne mo¿liwoœci leczenia ch³oniaków o przebiegu powolnym ze szczególnym 
uwzglêdnieniem analogów purynowych i przeciwcial monoklonalnych.
Analogi purynowe (fludarabina, 2-chloro-2'dezoksyadenozyna- 2CdA) s¹ bardzo obiecuj¹cymi preparatami ze wzglêdu na indukowanie 
apoptozy i dzia³anie cytotoksyczne wobec limfocytów spoczynkowych (nieaktywnych w cyklu komórkowym), które dominuj¹ w populacji 
komórek ch³oniaka o mniejszej z³oœliwoœci. W ci¹gu ostatnich kilku lat coraz szersze zastosowanie w leczeniu ch³oniaków nieziarniczych 
znajduj¹ przeciwcia³a monoklonalne przeciwko antygenom obecnym na powierzchni komórek ch³oniakowych np. anty CD20 (rituximab, 
Mabthera) lub anty CD52 (alemtuzumab, MabCampath).
S³owa kluczowe: ch³oniaki nieziarnicze, leczenie, analogi purynowe, przeciwcia³a monoklonalne.
Proceedings from the Conference "Current Achievements in Oncology" Poznañ, 6-8 November 2003
Praca prezentowana na konferencji "Wspó³czesne Osi¹gniêcia w Onkologii" Poznañ, 6-8 listopada 2003
Non-Hodgkin's lymphomas (nHl) forms a heterogenous rentiation or transformation of B or T lymphocytes and,
group of carcinomas originating from lymphocytes, their in rarer cases, of histiocytes. At Poland's latitude, 86% of all 
precursors or cells which are formed as a result of diffe- cases are those of the B-cell type. Clinically, i.e depending 
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on the course of the disease and the response to treatment, watch”, until the disease progresses to a more advance 
lymphomas can be classified into aggressive lymphomas stage.
and indolent lymphomas. In order to determine the aim of the prognosis, and thus 
Following the REAL classification indolent lymphomas treatment planning procedures, an International Prognostic 
include: Index (IPI) is employed, which takes into account
- small-lymphocyte lymphomas/ chronic lymphatic leu- the following parameters: age, general condition, number
kaemia, of extranodal locations, clinical stage according to Ann 
- limphoplasmocytoidal lymphoma / Waldenstrom's ma- Arbor, and the activity of lactate dehydrogenase. The IPI was 
croglobulinemia, originally designed to be used in aggressive lymphomas. 
- hairy cell leukemia lymphoma, Thus this index is generally regarded as one that does not 
- splenic marginal zone B-cell lymphoma, make possible predict the clinical course of indolent 
- marginal zone B-cell lymphoma: lymphomas Therefore, in 2002 a new prognostic index
- extranodal marginal zone B-cell lymphoma of MALT for follicular lymphomas was proposed [5,6]. See Table 1.
type,
- nodal marginal zone B-cell lymphoma.
Stage I and II follicular lymphoma is the most often en-
countered type of indolent lymphoma. Mycosis fungoides is 
an example of indolent lymphoma originating from T lym-
phocytes [1].
Chromosomal mutations (eg. translocations, deletions) 
lead to the activation of oncogens or loss of suppressor 
genes, which, as a consequence, results in the disturban-
ces in proliferation, differentiation and cell death (apo-
ptosis). In indolent lymphomas the dominant process is 
thought to be that of the impairment of the apoptosis , which 
more often than not, involves bcl2 overexpression. Modern 
techniques of molecular biology (FISH, PCR) make it possi- Age ³ 60 years 
ble to detect cytogenetical disorders in 80-90% of lympho- Haemoglobine £ 12 g/dL
mas, eg. (14,18) translocation with Bc12 oncogene activa- LDH > normal
tion observed in follicular lymphomas. These disturbances Stage (according to Ann Arbor) III - IV
rarely involve only one clonal aberration, they are mostly Number of involved nodal groups ³ 5
of a complex nature. In the course of the disease new 
changes appear [2]. The indications for chemotherapy for indolent lympho-
Indolent lymphomas, which made up about 40% of all mas are as follows: haematopoetic insufficiency (anaemia, 
lymphomas, belong to lymphoproliferative disorders with leukopenia, thrombocytopenia), occurence of B signs (fe-
relatively good prognosis and natural course lasting many ver, night sweats, weight loss), fast progression of the dise-
years. They are usually found in elderly people, whereas ase, large tumor mass, and patient's wish. In most cases
in 90% of all cases the diagnosis is established in the ad- a positive clinical outcome can be obtained by administe-
vanced clinical stage of the disease (stages III and IV accor- ring alkylating drugs such as cyclophosphamide and/or 
ding to Ann Arbor). Indolent lymphomas are curable only chlorambucil, sometimes in combination with steroids or
in early stages, when radiotherapy is the treatment by applying polychemotherapy, eg. COP (cyclophospha-
of choice. In stages I and II 30 Gy target irradiation allows us mide + vincristine + prednisone). Treatment of this type 
to obtain a 10-year disease free survival (DFS) in some 50% makes it possible to obtain a mean overall survival of be-
of all patients. Attempts at a combined modality therapy tween 5.6 and 10 years [3].
of early stages of lymphomas, eg. radiotherapy +COP-Bleo Purine analogues (fludarabine, 2-chloro-2'desoxyadeno-
/CHOP-Bleo, do not lead to unequivocal results. Early com- sine-2CdA) are very promising as they induce apoptosis 
bined treatment seems to prolong DFS, it does not, howe- and have cytotoxic activity against noncycling lymphocytes 
ver, have much effect on the overall survival (OS) [3,4]. (non-active in the cell cycle), which are dominant in the po-
In patients in advanced stages of the disease chemo- pulation of less malignant lymphoma cells. Fludarabine 
therapy is administered. In the case of indolent lymphomas used in monotherapy as next line treatment makes it po-
aggressive chemotherapy exposes patients to serious ssible to obtain about 50% of positive clinical responses. 
adverse effects rather than improves long-term results. This figure rises to 70% in patients who have not been 
Since this treatment is palliative in nature, in cases when treated earlier, 38% of them having registered complete 
the disease is stable, the onset of the therapeutic process remission. Similar results have been obtained with the use 
can be postponed, according to the approach of “wait and of 2CdA [7]. Despite the high percentage of total and partial 
Table 1. The Follicular Lymphoma International Prognostic Index (FLIPI).
 OS - overall survival
Risk group No of factors
OS
5 years % 10 years %
low
medium
high
0 - 1
2
> 2
91
78
53
71
51
36
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remissions a relapse of lymphoma occurs in most patients. in other modalities of combined treatment with anticancer 
High hopes for improved results are linked with the use drugs such as CHOP, CVP or fludarabine or immunomodu-
of purine analogues combined with other anticancer drugs. lating drugs, eg. interferons [10,11,12]. In the first-line treat-
The theoretical rationale for using fludarabine combined ment Czuczman et al. administered rituximab combined 
with mitoxantrone or cyclophosphamide is based on the with CHOP, and thus they were able to obtain 100% of po-
inhibitory effect of fludarabine in the repair mechanism sitive clinical responses including 66% of total remissions. 
of DNA impaired by alkylating drugs or mitoxantrone. Similarly, over 90% of positive outcomes was achieved 
The efficacy of fludarabine combined with, among other using rituximab in combination with fluradabine [13]. What 
drugs, cyclophosphamide; mitoxantrope and dexametha- is worth noting is that almost half of the patients undergoing  
sone (FND); cyclophosphamide and mitoxantrone (FMC); combined treatment were found to respond by molecular 
and cisplatine (FLUDAP) has been studied. The administra- remission in the form of eradication of bcl-2 positive cancer 
tion of FND in relapsed NHL resulted in 94% responses, cells  from the peripheral blood and bone marrow.
46% of which led to complete remission with the mean At present attempts are being made to increase
survival of 21 months [8]. The present opinion holds that the antibody activity by combining them with a radioisotope, 
the combination of fludarabine with steroids enhances eg. ibritumobab (Zevalin) or tositumobab (Bexxar) or im-
the immunosuppresive effect without significantly increa- munotoxin. The administration of ibritumobab (antibody 
90sing the anticancer effect. That is why the Southwest against CD20 conjugated with Yttrium Y) in a group of pa-
Oncology Group has suggested applying the FM (fludara- tients with follicular lymphoma made it possible to obtain
bine + mitoxantrone) protocol in the first line treatment a clinical response in 74% of patients. In relapsed or resis-
of indolent lymphomas, which resulted in 44% of complete tant indolent lymphomas ibritumomab provides statistically 
remissions and 50% of partial remissions. Despite this high a greater number of positive responses than ritiximab
efficacy of FM combination the comparison with historical (80% vs. 56%) [14].
groups treated using CHOP, PROMACE-MOPP protocols Interferon alpha in combination with cytotoxic agents 
did not show any improvement in the progression free improves the clinical outcome in patients with follicular 
survival (PFS) and overall survival (OS) in the group treated lymphoma. On ECOG study the administration of interferon 
with fludarabine and mitoxantrong [9]. alpha resulted in longer progression free survival. However, 
In the last few years monoclonal antibodies against on SWOG study these observations were not validated [7].
antigens presented on the lymphoma cells, eg. rituximab Megachemotherapy supported by autologic peripheral 
(Mabthera) antiCD20 or antiCD52 (alemtuzumab, Mab- stem cell transplantation used in relapsed or progression 
Campath) have become becoming widely used. Rituximab lymphomas makes it possible to obtain more than 90% 
is a chimera-type (mouse-human) monoclonal antibody positive responses, albeit most patients have recurrences 
selectively bound to CD20 antigen present on preB cells of the disease. The effectiveness of megachemotherapy
and mature B lymphocytes. The CD20 antigen is found in combination with auto or allotransplantation of the bone 
in 95% of all line B lymphomas. This antigen is not inter- marrow or stem cells from the peripheral blood has been 
nalised when combined with an antibody, it is not released subjected to clinical investigations. In a similar way, the effi-
from the surface of the cell, and does not exist in a free form cacy of new anticancer drugs such as rapamycin analo-
in the plasma. Rituximab molecule, which activates the me- gues, bcl-2 antisense oligonucleotides, antiidiotypic or DNA 
chanism of cell lysis as a result of antibody dependent cell vaccines has been determined. Proteasome inhibitor (bor-
cytotoxicity (ADCC) and the complement dependent cell tezomid) inhibits proliferation and induces lymphoma cell 
cytotoxicity (CMCC), also has a direct antiproliferative effect apoptosis. Phase II studies have shown that bortezomid is 
on cancer cells. Multicentre studies have demonstrated effective in many types of relapsed non-Hodgkin's  
40% to 60% of positive responses in monotherapy of relap- lymphomas, including those of the indolent course, and
sed and resistant lymphomas using rituximab, which the percentage of clinical responses ranges between 40% 
as a drug targeted at lymphoma cells does not enhance and 53% [15,16,17].
myelotoxicity involved in chemotherapy. The reports pu- Despite high susceptibility of indolent non-Hodgkin's 
blished so far claim that the adverse effects related lymphomas to chemo or radiotherapy and the relatively long 
to the haematopoietic system are rare, moderate and tran- survival, the available methods do not afford permanent 
sient. Severe thrombocytopenia and neutropenia have cure except for the cases in early clinical stages. Most pa-
been found in 1.8% of patients, whereas severe anaemia tients suffer from subsequent, even late, relapses, progre-
was observed in 1.4% of cases. In vitro studies have shown ssion of histologic malignancy (Richter's syndrome), as well 
that rituximab increases the anticancer drugs' sensitivity as progressive resistance to treatment. The full use
of human cell lines obtained from B limphocytes resistant of the latest advances in molecular biology and immu-
to chemotherapy. As a result a rationale for introducing nology has also brought with them significant advancement 
combined rituximab + chemotherapy has been establi- in the diagnosis of the pathogenesis of non-Hodgkin's 
shed. At present rituximab is used both in monotherapy and lymphomas. The introduction of new drugs and attempts
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in untreated stages III and IV low-grade lymphoma: S9501.at individualised therapy dependent on the type of lympho-
J Clin Oncol 2003;21:1996-2003.ma and risk factors raise hopes for better results in the treat-
10. McLaughlin P, Grillo-Lòpez AJ, Link BK, Levy R, Czuczman MS, ment of lymphomas.
Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal 
antibody therapy for relapsed indolent lymphoma: half of pa-
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